A Systematic Overview of Radiation Therapy Effects in Hodgkin's Lymphoma

References

• Cancer incidence in Sweden 1999. Stockholm: National Board of Health and Welfare, Centre for Epidemiology. The Cancer Registry, 2001.
   Google Scholar
• Amini R-M, Enblad G, Gustavsson A, et al. Treatment outcome in patients younger than 60 years with advanced stages (IIB -IV) of Hodgkin's disease: The Swedish national health care programme experience. Eur J Haematol 2000; 65: 379–89 (R2/307).
   Google Scholar
• Glimelius B, Kälkner M, Enblad G, et al. Treatment of early and intermediate stages of supradiaphragmal Hodgkin's dis-ease: the Swedish national care programme experience. Ann Oncol 1994; 5: 809-16 (R2/210).
   Google Scholar
• Molin D, Enblad G, Gustavsson A, et al. Early and inter-mediate stage Hodgkin's lymphoma-report from the Swedish National Care Programme. Eur J Haematol 2003; 70: 172-80 (R2/308).
   Google Scholar
• Enblad G, Gustavsson A, Sundstrom C, Glimelius B. Patients above sixty years of age with Hodgkin's lymphoma treated with a new strategy. Acta Oncol 2002; 41: 659-67 (R2/139).
   Google Scholar
• Carli PM, Coebergh JWW, Verdecchia A and the EUROCARE working group. Variation in survival of adult patients with haematological malignancies in Europe since 1978. Eur J Cancer 1998; 34: 2253–63 (01).
   Google Scholar
• Kennedy BJ, Fremgen AM, Menck HR. The National Cancer Data Base report on Hodgkin's disease for 1985-1989 and 1990-1994. Cancer 1998; 83: 1041–7 (01).
   Google Scholar
• Brandt L, Kimby E, Nygren P, et al. A systematic overview of chemotherapy effects in Hodgkin's disease. Acta Oncol 2001; 40: 185-97 (01).
   Google Scholar
• Hasenclever D, Diehl V for the International prognostic factors project on advanced Hodgkin's disease. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506-14 (R1/4695).
   Google Scholar
• Franklin J, Paulus U, Lieberz D, Breuer H, Tesch H, Diehl V for the German Hodgkin Lymphoma Study Group. Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? Ann Oncol 2000; 11: 617-23 (P1/712).
   Google Scholar
• Ng AK, Hoppe RT, Mauch PM. Life expectancy of patients with Hodgkin's disease. In: Mauch PM, Armitage JO, Diehl V, et al., (eds). Hodgkin's disease. Philadelphia: Lippincott Williams and Wilkins; 1999. p. 585-605 (L1).
   Google Scholar
• Aviles A, Delgado S. A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin's disease. Clin Lab Haem 1998; 20: 95–9. (Excluded randomized study).
   PubMedGoogle Scholar
• Specht L, Gray RG, Clarke MJ, Peto R for the International Hodgkin's Disease Collaborative Group. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3 888 patients. J Clin Oncol 1998; 16: 830–43 (M1/3888).
   Google Scholar
• Brincker H, Bentzen SM. A re-analysis of available dose-response and time-dose data in Hodgkin's disease. Radiother Oncol 1994; 30: 227-30 (02).
   Google Scholar
• Dtihmke E, Diehl V, Loeffler M, et al. Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys 1996; 36: 305–10 (C2/345).
   PubMedGoogle Scholar
• Mendenhall NP, Rodrigue LL, Moore-Higgs GJ, et al. The optimal dose of radiation in Hodgkin's disease: an analysis of clinical and treatment factors affecting in-field disease control. Int J Radiat Oncol Biol Phys 1999; 44: 551-61 (R2/169).
   Google Scholar
• Sieber M, Rueffer U, Tesch H, et al for the GHSG. Two cycles ABVD plus extended field radiotherapy is superior to radio-therapy alone in early stage Hodgkin's disease: interim analysis of the HD7 trial of the German Hodgkin's lymphoma study group (GHSG). Leuk Lymphoma 2001; 42 (Suppl 2): 52. Abstract.
   Google Scholar
• Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxor-ubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to HA Hodgkin's disease. J Clin Oncol 2001; 19: 4238-44 (C2/326).
   Google Scholar
• Radford JA. UK studies in early stage/low risk Hodgkin's lymphoma. Leuk Lymphoma 2001; 42 (Suppl 2): 12–3. Abstract.
   Google Scholar
• Enrici RM, Anselmo AP, Donato V, et al. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD. Haematologica 1999; 84: 917-23 (C3/ 73).
   Google Scholar
• Noordijk EM, Carde P, Mandard A-M, et al. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. Ann Oncol 1994; 5 (Suppl 2): 107–12 (C3/254).
   Google Scholar
• Noordijk EM, Carde P, Hagenbeek A, et al. Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin's disease. Six-year results of the EORTC-GPMC controlled clinical trials `147-VF', 1-17-F'and 'H7-U'. Int J Radiat Oncol Biol Phys 1997; 39 (Suppl 173): Abstract.
   Google Scholar
• Meerwaldt JH, Eghbali H, Fermé C, et al. for the EORTC lymphoma group and the Groupe d'études des lymphomes de l'adulte (GELA). Three cycles of MOPP/ABV hybrid and involved-field irradiation is more effective than subtotal nodal irradiation in favourable supradiaphragmatic clinical stages I-II Hodgkin's lymphoma: preliminary results of the EORTC-GELA H8-F randomized trial (# 20931) in 543 patients. Leuk Lymphoma 2001; 42 (Suppl 2): 12. Abstract.
   Google Scholar
• Horning SJ, Hoppe RT, Mason J, et al. Stanford-Kaiser Permanente G1 study for clinical stage I to HA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol 1997; 15: 1736-44 (C3/78).
   Google Scholar
• Rüffer J-U, Sieber M, Pfistner B, et al for the German Hodgkin's study group (GHSG). Extended versus involved field radiation following chemotherapy for intermediate stage Hodgkin's disease: interim analysis of the HD8 trial. Leuk Lymphoma 2001; 42 (Suppl 2): 54. Abstract.
   Google Scholar
• Bonfante V, Viviani S, Devizzi L, et al. Ten-years' experience with ABVD plus radiotherapy: subtotal nodal (STNI) vs involved field (IFRT) in early stage Hodgkin's disease (Hd). 367th Ann Meeting Am Soc Clin Oncol 2001; Abstract 1120.
   Google Scholar
• Loeffler M, Diehl V, Pfreundschuh M, et al. Dose-response relationship at complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. J Clin Oncol 1997; 15: 2275-87 (C1/258).
   Google Scholar
• Aisenberg AC. Problems in Hodgkin's disease management. Blood 1999; 93: 761-79 (L1).
   PubMedGoogle Scholar
• Fabian CJ, Mansfield CM, Dahlberg S, et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin's disease. Ann Intern Med 1994; 120: 903-12 (C2/ 278).
   Google Scholar
• Raemaekers J, Burgers M, Henry-Amar M, et al. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. Ann Oncol 1997; 8 (Suppl 1): 111–4 (P2/122).
   Google Scholar
• Zinzani PL, Magagnoli M, Chierichetti F, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999; 10: 1181-4 (01/44).
   Google Scholar
• Loeffler M, Brosteanu O, Hasencleaver D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. J Clin Oncol 1998; 16: 818-29 (M1/1740)
   Google Scholar
• Andrieu JM, Yilmaz U, Colonna P. MOPP versus ABVD and low-dose versus high-dose irradiation in Hodgkin's disease at intermediate and advanced stages: analysis of a meta-analysis by clinicians. J Clin Oncol 1999; 17: 730–2.
   Google Scholar
• Loeffler M, Brosteanu O, Hasencleaver D. In reply. J Clin Oncol 1999; 17: 732–4.
   Google Scholar
• Brice P, Colin P, Berger F, et al. Advanced Hodgkin disease with large mediastinal involvement can be treated with eight cycles of chemotherapy alone after a major response to six cycles of chemotherapy. Cancer 2001; 92: 453–9 (C3/-).
   PubMedGoogle Scholar
• Fermé C, Sebban C, Hennequin C, et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the Groupe d'etudes des lymphomes de l'adulte H89 trial. Blood 2000; 95: 2246–52 (C2/418).
   Google Scholar
• Gobbi PG, Pieresca C, Ghirardelli ML, et al. Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease. Blood 1998; 8: 2704-12 (P2/145).
   Google Scholar
• Mendenhall NP, Bennett CJ, Lynch JW. Is combined modality therapy necessary for advanced Hodgkin's disease? Int J Radiat Oncol Biol Phys 1997; 38: 583-92 (R2/55).
   Google Scholar
• Coleman M, Rafla S, Propert KJ, et al. Augmented therapy of extensive Hodgkin's disease: radiation to known disease or prolongation of induction chemotherapy did not improve survival-results of a cancer and leukemia group B study. Int J Radiat Oncol Biol Phys 1998; 41: 639-45 ((C3/258).
   Google Scholar
• Diehl V, Loeffler M, Pfreundschuh M, et al. Further che-motherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alter-nating chemotherapy in patients with advanced Hodgkin's disease. Ann Oncol 1995; 6: 901-10 (C2/100).
   Google Scholar
• Raemaekers JMM, Aleman BM P, Henry-Amar M, et al, for the EORTC lymphoma group. Involved field irradiation (IFRT) versus no further treatment in patients with stage III/ IV Hodgkin's lymphoma in complete remission after MOPP/ ABV: first results of the randomized EORTC trial # 20884. Leuk Lymphoma 2001; 42 (Suppl 2): 14–5. Abstract.
   Google Scholar
• O'Brien PC, Parnis FX. Salvage radiotherapy following chemotherapy failure in Hodgkin's disease-What is its role? Acta Oncol 1995; 34: 99-104 (R3/11).
   Google Scholar
• Pezner RD, Lipsett, JA, Vora N, Forman SJ. Radical radio-therapy as salvage treatment for relapse of Hodgkin's disease initially treated by chemotherapy alone: prognostic significance of the disease-free interval. Int .1 Radiat Oncol Biol Phys 1994; 30: 965–70 (R3/10).
   Google Scholar
• Wirth A, Corry J, Laidlaw C, et al. Salvage radiotherapy for Hodgkin's disease following chemotherapy failure. Int J Radiat Oncol Biol Phys 1997; 39: 599-607 (R2/52).
   Google Scholar
• Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line pro-gram for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97: 616-23 (R2/65).
   Google Scholar
• Mundt AJ, Sibley G, Williams S, et al. Patterns of failure following high-dose chemotherapy and autologous bone mar-row transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease. Int J Radiat Oncol Biol Phys 1995; 33: 261-70 (R3/54).
   Google Scholar
• Nademannee A, O'Donnell MR, Snyder DS, et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood 1995; 85: 1381-90 (R3/85).
   Google Scholar
• Pezner RD, Nademanee A, Niland JC, et al. Involved field radiation therapy for Hodgkin's disease autologous bone marrow transplantation regimens. Radiother Oncol 1995; 34: 23-9 (R3/29).
   Google Scholar
• Poen JC, Hoppe RT, Horning SJ. High-dose therapy and autologous bone marrow transplantation for relapsed/refrac-tory Hodgkin's disease: the impact of involved field radio-therapy on patterns of failure and survival. Int J Radiat Oncol Biol Phys 1996; 36: 3-12 (R2/100).
   Google Scholar
• Reece DE, Connors JM, Spinelli JJ, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83: 1193-9 (R3/28).
   Google Scholar
• Tsang RW, Gospodarowicz MK; Suthcliffe SB, et al. Thoracic radiation therapy before autologous bone marrow transplanta- tion in relapsed or refractory Hodgkin's disease. Eur J Cancer 1999; 35: 73-8 (R2/59).
   Google Scholar
• Horning SJ, Chao NJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801–13 (R2/-).
   PubMed Web of Science ®Google Scholar
• Constine LS, Rapaport A P. Hodgkin's disease, bone marrow transplantation, and involved field radiation therapy: coming full circle from 1902 to 1996. Int J Radiat Oncol Biol Phys 1996; 36: 253-5 (01).
   Google Scholar
• Zackrisson B, Mattsson S, Kjellén E, et al. and the Swedish Cancer Society Investigation Group. Research and develop-ment of radiation therapy in clinical routines. Acta Oncol 2003; 42: 115–22.
   Google Scholar
• Hughes DB, Smith AR, Hoppe R, et al. Treatment planning for Hodgkin's disease: a patterns of care study. Int J Radiat Oncol Biol Phys 1995; 33: 519-24 (R1/275).
   Google Scholar
• Amies C, Rose A, Metcalf P, Barton M. Multicentre dosimetry study of mantle treatment in Australia and New Zealand. Radiother Oncol 1996; 40: 171-80 (01).
   PubMedGoogle Scholar
• Barton MB, Rose A, Lonergan D, et al, on behalf of the Australasian radiation oncology lymphoma group. Mantle planning: report of the Australasian radiation oncology lymphoma group film survey and consensus guidelines. Aus-tralas Radiol 2000; 44: 433-8 (01).
   Google Scholar
• Hennequin C, Carrie C, Hofstetter S, Cosset JM. Le controle de qualite de la radiotherapie dans la Maladie de Hodgkin. Cancer Radiother 1999; 3: 187-90 (R1/161).
   Google Scholar
• Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 1997; 8 (suppl 1): 115–8 (R1/ 2498).
   Google Scholar
• van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994; 12: 312-25 (R1/1939).
   Google Scholar
• Brierley JD, Rathmell AJ, Gospodarowicz MK, et al. Late effects of treatment for early-stage Hodgkin's disease. Br J Cancer 1998; 77: 1300-10 (R1/611).
   Google Scholar
• Hancock SL, Hoppe RT. Long-term complications of treat-ment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 1996; 6: 2252 (R1/–).
   Google Scholar
• Swerdlow AJ, Barber JA, Vaughan Hudson G, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000; 18: 498-509 (R1/5519).
   Google Scholar
• Bhatia S. Late effects of hematopoietic cell transplantation. Educational Book. Am Soc Clin Oncol 2001; 373-85 (L1).
   Google Scholar
• Krishnan A, Bhatia S, Slovak M L, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95: 1588-93 (R1/612).
   Google Scholar
• van Leeuwen FE, Klokman WJ, van't Veer M B, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18: 487–97 (R1/-).
   Google Scholar
• Travis L. Therapy-associated secondary solid cancer. Acta Oncol 2002; 41: 323-33 (01).
   Google Scholar
• Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev 2000; 26: 291-302 (L1).
   Google Scholar
• Christie DRH, Wills R, Drew J F, Barton M B. The doses received by the breast during mantle radiotherapy. Int J Radiat Oncol Biol Phys 1998; 41: 223-6 (01).
   Google Scholar
• Reinders JG, Heijmen BJM, Olofsen-van Acht MJJ, et al. Ischemic heart disease after mantlefield irradiation for Hodg-kin's disease in long-term follow-up. Radiother Oncol 1999; 51: 35-42 (R2/258).
   Google Scholar
• Glanzmann C, Kaufmann P, Jenni R, Hess OM, Huguenin P. Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiother Oncol 1998; 46: 51-62 (R1/352).
   Google Scholar
• King V, Constine LS, Clark D, et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease. Int J Radiat Oncol Biol Phys 1996; 36: 881-9 (R1/326).
   Google Scholar